NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 967.3 DKK | -0.91% |
|
-0.28% | +38.56% |
| Jul. 11 | Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup | DJ |
| Jul. 11 | European Equities Close Higher Thursday; UK GDP Grows More Than Expected | MT |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-1.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.56% | 625B | |
| +60.25% | 841B | |
| -4.49% | 360B | |
| +18.30% | 327B | |
| +9.64% | 300B | |
| +14.15% | 242B | |
| +3.11% | 228B | |
| +16.98% | 227B | |
| +12.87% | 174B | |
| -0.45% | 162B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- 2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours
